BR112017005200A2 - composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo. - Google Patents

composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo.

Info

Publication number
BR112017005200A2
BR112017005200A2 BR112017005200A BR112017005200A BR112017005200A2 BR 112017005200 A2 BR112017005200 A2 BR 112017005200A2 BR 112017005200 A BR112017005200 A BR 112017005200A BR 112017005200 A BR112017005200 A BR 112017005200A BR 112017005200 A2 BR112017005200 A2 BR 112017005200A2
Authority
BR
Brazil
Prior art keywords
iron
increasing serum
mammal
composition
need
Prior art date
Application number
BR112017005200A
Other languages
English (en)
Inventor
Radics Gabor
Gilmer Jonh
Wang Jun
Ledwidge Mark
WHELEHAN Michael
O'flynn Pat
Original Assignee
Solvotrin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvotrin Therapeutics Ltd filed Critical Solvotrin Therapeutics Ltd
Publication of BR112017005200A2 publication Critical patent/BR112017005200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composições contendo ferro e proteína desnaturada foram preparadas que são capazes de aumentar ferro sérico e outros cátions de metal divalentes em um indivíduo. por exemplo, microesferas comestíveis foram preparadas contendo ferro detido dentro de uma matriz de proteína que provê um efeito gastroprotetor e melhora a biodisponibilidade de ferro em relação a veículos anteriormente conhecidos para administrar ferro a um indivíduo.
BR112017005200A 2014-09-15 2015-09-15 composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo. BR112017005200A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416293.7A GB201416293D0 (en) 2014-09-15 2014-09-15 Methods and preparations
US201562146897P 2015-04-13 2015-04-13
PCT/EP2015/071141 WO2016041995A1 (en) 2014-09-15 2015-09-15 Compositions and methods for increasing iron intake in a mammal

Publications (1)

Publication Number Publication Date
BR112017005200A2 true BR112017005200A2 (pt) 2018-03-06

Family

ID=51869639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005200A BR112017005200A2 (pt) 2014-09-15 2015-09-15 composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo.

Country Status (13)

Country Link
US (1) US11224614B2 (pt)
EP (1) EP3193839A1 (pt)
CN (1) CN107072953A (pt)
AU (1) AU2015316871A1 (pt)
BR (1) BR112017005200A2 (pt)
CA (1) CA2961430A1 (pt)
EA (1) EA201790615A1 (pt)
GB (1) GB201416293D0 (pt)
IL (1) IL251193A0 (pt)
MX (1) MX2017003433A (pt)
SG (1) SG11201702092UA (pt)
WO (1) WO2016041995A1 (pt)
ZA (1) ZA201702585B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892065A1 (ru) * 2016-03-15 2019-04-30 Солвотрин Терапьютикс Лтд Композиции и способы для увеличения поглощения железа в организме млекопитающего
AU2017256767B2 (en) * 2016-04-29 2024-07-25 Rousselot B.V. Protein based excipient for active pharmaceutical ingredients
BE1023653B1 (nl) * 2016-04-29 2017-06-07 Rousselot B.V. Eiwit gebaseerd excipient voor actieve farmaceutische stoffen
WO2018113890A1 (en) * 2016-12-23 2018-06-28 University Of Copenhagen A co-amorphous form of a substance and a protein
IT201700039524A1 (it) * 2017-04-10 2018-10-10 Labomar S R L Composizioni orali per il trattamento di disturbi da carenza di ferro
CN108157727A (zh) * 2017-11-30 2018-06-15 慈中华 用于保持平和体质的固体饮料及其加工方法
US11350657B2 (en) 2018-08-06 2022-06-07 Pharmavite, Llc Protein gummy composition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US505986A (en) 1893-10-03 Pio marfori
US4167564A (en) 1974-09-23 1979-09-11 Albion Laboratories, Inc. Biological assimilation of metals
US4067994A (en) 1976-03-26 1978-01-10 Zinpro Corporation Iron methionine complex salts
US4216144A (en) 1977-10-20 1980-08-05 Ashmead H H Soluble iron proteinates
IT1150213B (it) 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
IT1186787B (it) 1985-11-06 1987-12-16 Mediolanum Farmaceutici Srl Ferro-derivati della globina e dell'acetilglobina dotati di elevata biodisponibilita',processo di preparazione e composizioni farmaceutiche
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
JP3404294B2 (ja) 1998-08-11 2003-05-06 雪印乳業株式会社 鉄−ホエー蛋白質加水分解物複合体
US6521247B1 (en) 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
EP2274988A3 (en) * 2003-10-30 2011-03-30 Arla Foods Amba Stabilisers useful in low fat spread production
CN1557481A (zh) 2004-02-04 2004-12-29 高春平 防治缺铁性贫血的天然营养剂
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7585527B2 (en) 2005-09-19 2009-09-08 Bala Venkataraman Composition and method for treating iron deficiency anemia
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
CN101143011B (zh) 2007-10-09 2011-06-22 浙江大学 提高食物中铁素生物有效性的方法
US20090124572A1 (en) 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
CN101928742B (zh) 2009-06-23 2013-02-27 光明乳业股份有限公司 一种具有抗氧化性活性的乳清蛋白活性肽及其制备方法
US20120288531A1 (en) 2011-01-14 2012-11-15 Shmuel Tuvia pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
US9936726B2 (en) 2011-07-15 2018-04-10 Nextec S.A. Food-grade encapsulate and process for the production thereof
MX2014003327A (es) * 2011-09-22 2014-07-09 Amip Promotor de absorcion gi superior amortiguado.
WO2014148886A1 (en) * 2013-03-22 2014-09-25 N.V. Nutricia Fermented nutrition high in lactose with increased iron bioavailability
EP2995205A1 (en) 2014-09-15 2016-03-16 Anabio Technologies Limited Compositions and methods for the maintenance of adequate iron intake in a mammal

Also Published As

Publication number Publication date
US11224614B2 (en) 2022-01-18
CA2961430A1 (en) 2016-03-24
ZA201702585B (en) 2021-06-30
US20160073668A1 (en) 2016-03-17
CN107072953A (zh) 2017-08-18
GB201416293D0 (en) 2014-10-29
EA201790615A1 (ru) 2017-08-31
AU2015316871A1 (en) 2017-05-04
SG11201702092UA (en) 2017-04-27
EP3193839A1 (en) 2017-07-26
MX2017003433A (es) 2017-11-13
WO2016041995A1 (en) 2016-03-24
IL251193A0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
BR112017005200A2 (pt) composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo.
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
JOP20220241A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112018072196A2 (pt) amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
BR112017024747A2 (pt) composições e métodos para enriquecer populações de ácidos nucleicos
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
ZA202305280B (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
BR112017010669A2 (pt) composição, método para reduzir o número de patógenos sobre uma superfície e método para reduzir o número de patógenos em um volume de um produto alimentício
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
BR112015009954A2 (pt) Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit
GT201800102A (es) Polipéptidos que inhiben cd4ol
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements